Literature DB >> 7105090

Electrophysiological effects of labetolol on rabbit atrial, ventricular and Purkinje cells, in normoxia and hypoxia.

E M Vaughn Williams, J S Millar, T J Campbell.   

Abstract

Labetolol, which blocks both alpha and beta-adrenoceptors, was found to have direct actions on cardiac muscle which could themselves be antiarrhythmic. It depressed the maximum rate of depolarisation, and reduced conduction velocity, in atrial and ventricular muscle and in Purkinje cells, implying restriction of fast inward current (Class 1). It had twice the potency of procaine as a local anesthetic on nerve. Labetolol abbreviated the action potential (AP) plateau in normoxic atrial muscle, but attenuated AP-shortening by hypoxia. It caused a significant slowing of all phases of repolarisation (Class 3) in normoxic ventricular muscle. It had no negative inotropic action in normoxia or hypoxia, and there was no evidence for slowing of A-V nodal conduction.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7105090     DOI: 10.1093/cvr/16.5.233

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  4 in total

1.  Antiarrhythmic efficacy of labetalol as assessed by programmed electrical stimulation.

Authors:  G Krumpl; H Todt; K Krejcy; G Raberger
Journal:  Br J Pharmacol       Date:  1990-08       Impact factor: 8.739

2.  Electrophysiological effects of alpha-adrenoceptor antagonists in rabbit sino-atrial node, cardiac Purkinje cells and papillary muscles.

Authors:  I D Dukes; E M Vaughan Williams
Journal:  Br J Pharmacol       Date:  1984-10       Impact factor: 8.739

3.  Electrophysiological effects of labetalol on canine atrial, cardiac Purkinje fibres and ventricular muscle.

Authors:  J G Mill; F Riccioppo Neto
Journal:  Br J Pharmacol       Date:  1987-11       Impact factor: 8.739

Review 4.  Combined receptor intervention and myocardial infarction.

Authors:  D A Chamberlain; R Vincent
Journal:  Drugs       Date:  1984       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.